HB-EGF function in cardiac valve development requires interaction with heparan sulfate proteoglycans

Area of Science:

• Developmental biology
• Cell signaling
• Molecular biology

Background:

• Heparin-binding EGF-like growth factor (HB-EGF) is a key regulator in the EGF family.
• HB-EGF plays a critical role in cardiac valve development by inhibiting mesenchymal cell proliferation.

Purpose of the Study:

• To investigate the role of heparan sulfate proteoglycans (HSPGs) in HB-EGF function during cardiac valve development.
• To elucidate the mechanism by which HB-EGF interacts with HSPGs for proper valve formation.

Main Methods:

• Utilized an ex vivo model of endocardial cushion explants to disrupt HB-EGF and HSPG interactions.
• Generated homozygous knock-in mice (HB(Delta)(hb/)(Delta)(hb)) expressing a mutant HB-EGF unable to bind HSPGs.
• Compared phenotypes of HB(Delta)(hb/)(Delta)(hb) mice with Hbegf-null mice.

Main Results:

• Disruption of HB-EGF and HSPG interaction in vitro led to increased mesenchymal cell proliferation.
• HB(Delta)(hb/)(Delta)(hb) mice exhibited enlarged cardiac valves with hyperproliferation of mesenchymal cells, similar to Hbegf-null mice.
• Unlike Hbegf-null mice, HB(Delta)(hb/)(Delta)(hb) mice did not display defects in heart chambers or lung alveoli.

Conclusions:

• Heparan sulfate proteoglycans (HSPGs) are indispensable for HB-EGF's function in suppressing mesenchymal cell proliferation.
• HSPG interaction is crucial for HB-EGF's specific role in cardiac valve development.
• HB-EGF requires HSPG binding for proper cardiac valve formation, but not for other developmental processes affected in Hbegf-null mice.